Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - Piper Sandler has raised its price target on Hinge Health Inc (NYSE:HNGE) to $70.00 from $41.00 while maintaining an Overweight rating on the stock. Currently trading at $56.07, the company has demonstrated strong momentum with a 49% gain over the past six months. According to InvestingPro data, analysts maintain a bullish consensus on HNGE, with 10 analysts recently revising their earnings estimates upward.
The significant price target increase follows Hinge Health’s second-quarter 2025 earnings report, where the company raised its calendar year 2025 outlook for the second consecutive quarter this year.
Piper Sandler cited the company’s strong execution and improved operating margins as key factors in its decision to raise the price target multiple to 13.7x EV/CY26E gross profit, up from the previous 7.0x multiple.
The research firm’s analysis includes interim third-quarter 2025 app download data, which suggests potential upside to their published estimates that were aligned with the midpoint of company guidance.
Piper Sandler’s updated price target represents a significant 70.7% increase from its previous target, reflecting enhanced confidence in Hinge Health’s business performance and growth trajectory.
In other recent news, Hinge Health reported impressive second-quarter results that significantly exceeded market expectations. The company recorded revenue of $139.1 million, surpassing consensus estimates of $125.4 million, marking a 55% year-over-year growth. This strong performance led management to substantially raise their 2025 revenue and EBIT guidance, with implied second-half revenue growth expected to exceed 40%. Following these results, Stifel raised its price target for Hinge Health to $63 while maintaining a Buy rating. Similarly, Citizens JMP increased its price target to $65 and retained a Market Outperform rating. Citizens JMP had previously initiated coverage on Hinge Health with a Market Outperform rating and a price target of $58 after the company’s initial public offering. Truist Securities maintained its buy rating and $48 price target after a meeting with company executives, reinforcing its positive outlook. Truist also reiterated its buy rating following the launch of HingeSelect, a provider network for musculoskeletal care, which aims to enhance the member experience using software and AI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.